Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

New York, USA, June 02, 2026 (GLOBE NEWSWIRE) -- Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight The...
May 18, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

New York, USA, May 18, 2026 (GLOBE NEWSWIRE) -- Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals |...
October 25, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst, Cabaletta Bio, Janssen, Argenx, UCB Pharma, Alexion, Immunovant

New York, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst,...
July 22, 2021 20:00 ET | Source: DelveInsight Business Research LLP

Recent Clinical Trials Analysis on Myasthenia Gravis Treatment

Los Angeles, USA, July 22, 2021 (GLOBE NEWSWIRE) -- Recent Clinical Trials Analysis on Myasthenia Gravis Treatment Around 15+ key companies are developing the Myasthenia Gravis therapies. Argenx...